Dermatology and Therapy最新文献

{"title":"Transforming Aesthetic Dermatology: The Role of Artificial Intelligence in Skin Health.","authors":"Xiang Chen, Zhaokang Zhou, Hui Ding, Huiying Zheng, Yiping Ge","doi":"10.1007/s13555-025-01459-2","DOIUrl":"10.1007/s13555-025-01459-2","url":null,"abstract":"<p><p>Artificial intelligence (AI) has profoundly impacted various medical fields, including dermatology, which is to a large extent an image-based discipline. Initially applied in general dermatology, AI has expanded into aesthetic dermatology, where it assists in integrating objective approaches with the aesthetic judgment of dermatologists. This review explores the role of AI in aesthetic dermatology, focusing on skin condition assessment, diagnosis, treatment optimization, and patient education, as well as the challenges and future directions in this evolving field.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1999-2013"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of a Photolyase-Based Medical Device on Actinic Keratosis in Phototypes III-IV Patients: Real-Life Clinical Setting.","authors":"Fernando Bulla, Susana Mejía, Sebastian Gil-Quiñones, Sara Cataño, Susana Sierra","doi":"10.1007/s13555-025-01455-6","DOIUrl":"10.1007/s13555-025-01455-6","url":null,"abstract":"<p><strong>Introduction: </strong>Actinic keratoses (AK) are premalignant skin lesions that occur in chronically photo-exposed body areas. Topical sunscreens prevent but do not reverse ultraviolet radiation (UVR)-induced damage to deoxyribonucleic acid (DNA). Eryfotona is a sunscreen product that combines high solar protection factors with light-driven DNA repair enzymes known as photolyases. This photolyase-based medical device has been shown to reduce the absolute number of AK; however, a more comprehensive assessment of AK lesions is ideal for determining its actual effect in everyday practice. The purpose of the study is to evaluate the photoprotective effect of Eryfotona sunscreen on individual AK lesions, assessing changes in their clinical and dermoscopic presentation in a real-life clinical setting and the impact on the health-related quality of life.</p><p><strong>Methods: </strong>This was an observational, prospective, real-life study of adult patients with skin phototypes III or IV and actinic keratosis (AK) lesions on the face and scalp. Patients were treated with sunscreen containing photolyase twice daily for 6 months, with follow-up visits at 3 and 6 months. The clinical evaluation included the actinic keratosis and severity index (AKASI), the absolute number and individual dimensions of AK lesions, and the Olsen clinical classification scheme. The dermoscopic evaluation included the Zalaudek classification and assessment of lesion pigmentation. The AK Quality of Life (AKQoL) questionnaire was administered to patients during each follow-up. A repeated measures analysis of variance was performed to compare quantitative outcomes, and Fisher's exact tests were used for categorical variables.</p><p><strong>Results: </strong>A total of 45 patients with 205 AK lesions were included; 25 patients completed both follow-ups. Clinically, there was a significant improvement from an AKASI score of 2.55 at baseline to 1.90 at 6 months (p = 0.000), and a significant difference was also observed in the dimensions of individual AK lesions and the Olsen classification between the three evaluation times (p = 0.000). Dermoscopic assessment, as classified by the Zalaudek classification, showed significant improvement throughout the three evaluations (p = 0.000). In total, 53 lesions disappeared, corresponding to 26.36% of the lesions.</p><p><strong>Conclusions: </strong>Eryfotona provided effective and safe photoprotection and treatment of actinic keratosis on the face and scalp in patients with phototypes III and IV in the real-life clinical setting, showing promising effects on higher-grade lesions.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2131-2145"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Psoriasis on Sleep Quality: Examining the Relationship Between Psoriasis, Sleep, and Mental Health.","authors":"Andrea Leung, Kathryn Haran, Georgia Marquez-Grap, Kristen Chang, Chandler E Johnson, Allison Kranyak, Tina Bhutani, Wilson Liao","doi":"10.1007/s13555-025-01449-4","DOIUrl":"10.1007/s13555-025-01449-4","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic immune-mediated skin disease with known physical and mental health comorbidities, such as cardiovascular disease, depression, and anxiety. Psoriasis also has a significant impact on quality of life and sleep due to factors like itch and pain. This study aims to assess the relationship between sleep quality, mental health, and psoriasis, and specifically investigate the impact of poor sleep quality on mental health outcomes within participants with psoriasis.</p><p><strong>Methods: </strong>In this cross-sectional study, we enrolled 556 participants into two cohorts: 487 participants were enrolled into the psoriasis cohort, and 69 were enrolled into the healthy control cohort. The demographics, disease severity, family history, sleep quality (PROMIS 8a, PROMIS 8b, and Insomnia Severity Index), and mental health (Patient Health Questionnaire-8 and Generalized Anxiety Disorder-7) of participants were assessed. Descriptive analysis and logistic regression models were employed to examine sleep and mental health, adjusting for potential confounders like demographics and comorbidities.</p><p><strong>Results: </strong>A comparison of patients with psoriasis and healthy controls revealed worsened sleep and mental health outcomes in patients with psoriasis. Among participants with psoriasis, greater sleep impairment (Patient-Reported Outcomes Measurement Information System (PROMIS) 8a), sleep disturbance (PROMIS 8b), and insomnia were significantly associated with anxiety (ORa 1.22; 95% confidence interval (CI) 1.16, 1.30; ORa 1.26; 95% CI 1.16, 1.80; ORa 5.13; 95% CI 2.91, 9.33; respectively) and depression (ORa 1.42; 95% CI 1.32, 1.56; ORa 1.16; 95% CI 1.08, 1.26; ORa 7.04; 95% CI 4.01, 12.77; respectively).</p><p><strong>Conclusion: </strong>These findings underscore the importance of recognizing how psoriasis can impact mental health and sleep. Building a collaborative relationship between patients with psoriasis and their providers is essential to improve overall sleep and life quality.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2247-2254"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab?","authors":"Neenu Sebastian, Omar Chircop, Tim H Clayton, Firas C Kreeshan, Hamish J A Hunter, Richard B Warren","doi":"10.1007/s13555-025-01446-7","DOIUrl":"10.1007/s13555-025-01446-7","url":null,"abstract":"<p><strong>Introduction: </strong>Tralokinumab, a human IgG4 monoclonal antibody that inhibits the IL-13 pathway, is approved for the treatment of atopic dermatitis. However, real-world data are lacking and are needed to inform its efficacy and safety in broader populations.</p><p><strong>Methods: </strong>This retrospective study reviewed the Eczema Area and Severity Index (EASI) and Dermatology Life Quality Index (DLQI) at baseline and 16-20 weeks of 39 consecutive patients who received subcutaneous tralokinumab at the label dose in a tertiary centre.</p><p><strong>Results: </strong>Twenty-nine out of 39 patients had an EASI score recorded after 16-20 weeks. At 16-20 weeks, 65.5% (19/29) of patients achieved EASI 50, 37.9% (11/29) achieved EASI 75, and 27.8% (9/29) achieved EASI 90. DLQI was reduced by an average of - 10.4 points at 16-20 weeks. No serious adverse events were reported. Ocular adverse events were reported in 25.6% (10/39) of the cohort but did not lead to treatment discontinuation. Six out of seven patients that previously experienced conjunctivitis with dupilumab had no recurrence with tralokinumab.</p><p><strong>Conclusion: </strong>Our study supports using tralokinumab in atopic dermatitis with similar real-world efficacy to that shown in clinical trials. Tralokinumab offers an alternative for patients failing dupilumab because of conjunctivitis.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2275-2279"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.","authors":"Eric L Simpson, Jonathan I Silverberg, Vimal H Prajapati, Kilian Eyerich, Norito Katoh, Mark Boguniewicz, Emma Guttman-Yassky, E James Song, Wan-Ju Lee, Henrique D Teixeira, Tianshuang Wu, Cristina Sancho Sanchez, Namita Vigna, Brian M Calimlim, Marjolein de Bruin-Weller","doi":"10.1007/s13555-025-01443-w","DOIUrl":"10.1007/s13555-025-01443-w","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Achievement of stringent outcomes (e.g., ≥ 90% improvement from baseline in Eczema Area and Severity Index [EASI 90] or minimal-to-no itch on the Worst Pruritus Numerical Rating Scale [WP-NRS 0/1]) is associated with a substantial improvement in quality of life among patients with atopic dermatitis (AD). Using stringent outcomes, we evaluated the efficacy of upadacitinib vs placebo and vs dupilumab on rapid itch improvement and skin clearance in patients with moderate-to-severe AD in three phase 3 clinical trials.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Patients received orally administered upadacitinib 15 mg (UPA15), 30 mg (UPA30), or placebo once daily for 16 weeks in Measure Up 1 and Measure Up 2 and orally administered UPA30 once daily or subcutaneously administered 300 mg dupilumab every 2 weeks (after a 600 mg loading dose) for 24 weeks in Heads Up. Key outcomes included the proportion of patients achieving WP-NRS 0/1, WP-NRS 0, EASI 90, and EASI 100, as well as the proportion of patients achieving composite outcomes (EASI 90 and WP-NRS 0/1; EASI 100 and WP-NRS 0). Patients assessed WP-NRS daily for the first 16 weeks and at scheduled visits thereafter, and investigators assessed EASI at scheduled visits.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A greater proportion of patients receiving upadacitinib vs placebo and vs dupilumab achieved WP-NRS 0/1 at week 16 (nominal p &lt; 0.001 vs placebo) and week 24 (nominal p &lt; 0.001 vs dupilumab), with differences as early as the day after treatment initiation (day 2; nominal p &lt; 0.05 vs placebo and vs dupilumab), as well as WP-NRS 0 at week 16 (nominal p &lt; 0.001 vs placebo) and week 24 (nominal p &lt; 0.001 vs dupilumab), with differences as early as day 8 (nominal p &lt; 0.01 vs placebo; nominal p &lt; 0.001 vs dupilumab). A greater proportion of patients receiving upadacitinib vs placebo and vs dupilumab achieved EASI 90 at week 16 (p &lt; 0.001 vs dupilumab), with differences as early as week 1 (nominal p &lt; 0.01 vs placebo; nominal p &lt; 0.05 vs dupilumab), as well as EASI 100 at week 16 (p &lt; 0.001 vs placebo) and week 24 (nominal p &lt; 0.001 vs dupilumab), with differences as early as week 4 (nominal p &lt; 0.001 vs placebo and vs dupilumab). A greater proportion of patients also achieved EASI 90 and WP-NRS 0/1 by week 2 (UPA15: 2.7%, UPA30: 6.7% vs placebo: 0%, nominal p &lt; 0.001; UPA30: 7.1% vs dupilumab: 1.2%, nominal p &lt; 0.001) and EASI 100 and WP-NRS 0 by week 4 (UPA15: 1.6%, UPA30: 3.9% vs placebo: 0.2%, nominal p ≤ 0.01; UPA30: 4.7% vs dupilumab: 0.6%, nominal p &lt; 0.01) through all evaluated time points.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Patients with moderate-to-severe AD treated with upadacitinib rapidly achieved stringent itch improvement and skin clearance targets compared with those receiving placebo or dupilumab, with responses sustained through weeks 16 (Measure Up 1 and Measure Up 2) and 24 (Heads Up).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Clinical trial registration: &lt;/strong&gt;ClinicalTrials.gov; NCT03569293 ","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2061-2076"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry.","authors":"April W Armstrong, Steven R Feldman, Timothy Fitzgerald, Theodore Alkousakis, Adam Sima, Alvin Li, Hyung-Joo Kang, Sandra I Main, Saakshi Khattri, Linda Stein Gold","doi":"10.1007/s13555-025-01456-5","DOIUrl":"10.1007/s13555-025-01456-5","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis body surface area (BSA) of 10% or more has been a major criterion for determining systemic therapy eligibility. However, patients with BSA < 10% and even ≤ 3% may have high disease burden and difficulties accessing biologics. To assess psoriasis burden among patients with BSA ≤ 10%, this study characterized patient-reported outcomes (PROs) across BSA categories among systemic treatment-naïve patients initiating biologic therapy.</p><p><strong>Methods: </strong>Patients from the CorEvitas Psoriasis Registry initiating biologics between April 2015 and September 2023 were categorized according to low (< 3%), medium (3-10%), or high (> 10%) BSA involvement. Measures assessed at initiation of biologic therapy included health-related quality of life, itch, pain, fatigue, psoriatic arthritis, psoriasis disease characteristics, and medical history. Overlap between BSA groups for each outcome was calculated via non-parametric Mann-Whitney statistic transformation (range 0.0-1.0; 0.5 indicates complete similarity [i.e., for a comparison between low and high BSA groups, overlap of 0.5 means there is 50% probability that a randomly selected patient with low BSA would have the same or greater PRO burden as one with high BSA]; 0 or 1 indicates complete dissimilarity) to determine whether each measure differed in randomly selected patients with low or medium versus high BSA.</p><p><strong>Results: </strong>Of 1640 patients who initiated biologics, 7.0% had low BSA, 46.9% had medium BSA, and 46.2% had high BSA involvement. PRO overlap statistics ranged from 0.52 to 0.59 and from 0.60 to 0.70 for randomly selected patients with high versus medium and low BSA, respectively, indicating patients with high and medium BSA are likely to have similar levels of disease burden, and patients with high BSA are slightly more likely to have higher disease burden than those with low BSA. Near complete overlap (range 0.44-0.58) was observed for psoriasis disease characteristics and medical history in the low versus high and medium BSA groups.</p><p><strong>Conclusion: </strong>Observed overlap in PROs across BSA categories shows that patients with low BSA can experience similarly poor quality of life and high symptom burden to those with higher BSA. These findings support the appropriateness of considering biologic therapies for patients with low BSA and indicators of high disease burden.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT02707341.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2117-2130"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.","authors":"Tiago Torres, Jensen Yeung, Vimal H Prajapati, Simone Ribero, Anna Balato, Angelo Valerio Marzano, Maria João Cruz, Maria João Paiva Lopes, Elizabeth Lazaridou, Jose-Manuel Carrascosa, José Miguel Alvarenga, Pedro Farinha, Bruno Duarte, Monica Munera-Campos, Siddhartha Sood, Brian D Rankin, Michela Ortoncelli, Stefano Caccavale, Silvia Mariel Ferrucci, Gilberto Pires Rosa, Athina Ioanna Daponte, Gianmarco Silvi, Ketty Peris, Niccolò Gori, Francesca Prignano, Antonio Kolios, Pedro Herranz, Stamatios Gregoriou, Natalia Rompoti, Spyridon Gkalpakiotis, Andrea Chiricozzi","doi":"10.1007/s13555-025-01453-8","DOIUrl":"10.1007/s13555-025-01453-8","url":null,"abstract":"<p><strong>Introduction: </strong>Evaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial. In this international, multicenter, retrospective, comparative study we aimed to evaluate the 52-week effectiveness, safety, and tolerability of dupilumab, tralokinumab, and upadacitinib in patients with AD aged ≥ 12 years.</p><p><strong>Methods: </strong>Effectiveness was assessed at weeks 16, 24, and 52 using Eczema Area and Severity Index (EASI) and itch Numerical Rating Scale (NRS) scores. Safety was measured via adverse events (AEs).</p><p><strong>Results: </strong>A total of 1286 treatment courses were included: 62.5% received dupilumab, 24.3% received upadacitinib, and 13.1% received tralokinumab. Upadacitinib demonstrated higher effectiveness than dupilumab and tralokinumab across all time points and most evaluated outcomes both on the overall population and the biologic-/JAKi-naïve population, including stringent treatment targets such as EASI 90 response and combined EASI 90 + itch NRS 0/1 response. While upadacitinib demonstrated superior effectiveness, it was associated with a higher incidence of AEs, both leading to and not leading to treatment discontinuation, including thromboembolic events, lipid abnormalities, and hematologic abnormalities. In contrast, conjunctivitis was the most frequently observed AE among patients receiving biologics.</p><p><strong>Conclusion: </strong>This study provides a comprehensive real-world comparison of dupilumab, tralokinumab, and upadacitinib in AD, highlighting upadacitinib's superior effectiveness in achieving stringent treatment targets, both in the short and long term, but also a higher incidence of AEs. However, the considerable heterogeneity of the study population, an inherent limitation of real-world studies, must be acknowledged when interpreting these findings.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2295-2305"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scalp Microbiome Dynamics Can Contribute to the Clinical Effect of a Novel Antiseborrheic Dermatitis Shampoo Containing Patented Antifungal Actives: A Randomized Controlled Study.","authors":"Martine Maître, Sophie Baradat, Mélanie Froliger, Virginie Turlier, Aimée Simcic-Mori, Eléonore Gravier, Camille Géniès, Christophe Lauze, Céline Huyghe, Anaïs Noustens, Sandrine Alvarez-Georges, Rasvan Marinescu, Pascal Reygagne, Sandrine Bessou-Touya, Valérie Mengeaud, Hélène Duplan","doi":"10.1007/s13555-025-01408-z","DOIUrl":"10.1007/s13555-025-01408-z","url":null,"abstract":"<p><strong>Introduction: </strong>Scalp seborrheic dermatitis (SD) can cause physical discomfort and social embarrassment in affected individuals. Mild-to-moderate scalp SD can be managed using topical products with antifungal, antiinflammatory, and keratolytic properties.</p><p><strong>Methods: </strong>A two-phase, randomized, controlled study was conducted to evaluate the clinical efficacy of a newly formulated anti-SD shampoo containing two patented antifungal actives and to investigate the associated changes in the scalp microbiota. The intervention involved a 2-week intensive phase for the 42 subjects included in the study, consisting of the application of the anti-SD shampoo three times a week; a randomized [1:1], controlled, parallel-group 8-week maintenance phase consisting of the test group applying the study shampoo once a week alternately with a neutral shampoo twice a week; and the control group applying the neutral shampoo alone three times a week.</p><p><strong>Results: </strong>Following the intensive phase, the scalp condition improved substantially, as evidenced by a significant decrease in the severity of dandruff, erythema, and pruritus, associated with an improvement of SD dysbiosis. These improvements were more sustained in the test group than in the control group during the maintenance phase. The rediversification of the scalp microbiota involved a significant increase in fungal and bacterial richness along with a decrease in the level of SD-predominant Malassezia fungi and Staphylococcus bacteria and an increase in the level of low-abundant fungi genera belonging to the Ascomycota phylum.</p><p><strong>Conclusions: </strong>The synergistic effects of antimycotic and antiinflammatory agents in the study shampoo likely contributed to rebalancing the fungal and bacterial ecosystem, thus improving scalp symptoms.</p><p><strong>Clinicaltrials: </strong></p><p><strong>Gov identifier: </strong>NCT06578962 (retrospectively registered on 28 August 2024).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2077-2097"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Supplementation with a New Hyaluronic Acid Matrix Ingredient Improves Skin Brightness, Hydration, Smoothness, and Roughness: Results from a Randomized, Double-Blinded, Placebo-Controlled Study.","authors":"Trinidad Montero-Vilchez, Patricia Gálvez-Martín, Raquel Sanabria-de la Torre, Carlos Cuenca-Barrales, Alejandro Molina-Leyva, Daniel Martinez-Puig, Javier Velasco-Alvarez, Salvador Arias-Santiago","doi":"10.1007/s13555-025-01447-6","DOIUrl":"10.1007/s13555-025-01447-6","url":null,"abstract":"<p><strong>Introduction: </strong>The skin aging process is mainly associated with the appearance of fine wrinkles and flaccid, dry, and dull skin. A hyaluronic acid matrix (HAm) ingredient containing HA, sulfated glycosaminoglycans (GAGs), and collagen is proposed to enhance skin health by improving hydration and structural integrity. The objective of this study was to evaluate the impact of oral supplementation with HAm on skin properties.</p><p><strong>Methods: </strong>A 12-week, randomized, double-blind, placebo-controlled trial was designed, including 60 healthy women aged 35-65 with signs of natural skin aging (NCT05813054). Participants were assigned to receive either HAm (Dermial^®; 60 mg daily) or a placebo and were dermatologically assessed after 6 and 12 weeks. Skin properties were determined by the evaluation of stratum corneum hydration (SCH), brightness/glow, wrinkles, dryness, roughness, smoothness, pH, temperature, elasticity, friction, antioxidant capacity, deformability, melanin index, and erythema index. In addition, global satisfaction and adverse reactions were assessed.</p><p><strong>Results: </strong>Assessments were performed on data from 50 participants as a per-protocol analysis. Skin wrinkles and smoothness (6 weeks), and roughness (12 weeks) significantly improved in the HAm group compared with the placebo group. Participants receiving HAm had significantly increased skin SCH and brightness, and decreased scaliness and temperature at 6 and 12 weeks versus the baseline value. A statistically significant reduction in the erythema index and a balanced pH were also observed in the HAm group. Global satisfaction was significantly higher in HAm as compared to placebo. No serious adverse events associated with the tested products were registered during the study.</p><p><strong>Conclusions: </strong>Daily supplementation with HAm effectively improves multiple aspects of skin health and appearance, suggesting its potential as a safe and beneficial antiaging ingredient. These results support the role of HAm in promoting skin brightness/glow and hydration, and reducing the visible effects of aging.</p><p><strong>Trial registration: </strong>ClinicalTrials. gov identifier, NCT05813054.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2099-2116"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis.","authors":"Jonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, Andrew E Pink, Diego Ruiz Dasilva, Shawn G Kwatra, Yousef Binamer, Norito Katoh, Valeria Aoki, Alvaro Moreira, Ayman Grada, Chao Li, Brian Calimlim, Wan-Ju Lee, Christopher G Bunick","doi":"10.1007/s13555-025-01469-0","DOIUrl":"10.1007/s13555-025-01469-0","url":null,"abstract":"<p><strong>Introduction: </strong>Guidance from the Aiming Higher in Eczema/Atopic Dermatitis initiative identified moderate and optimal treatment targets for clinician-reported outcomes (ClinROs) and patient-reported outcomes (PROs) and defined minimal disease activity (MDA) as simultaneously meeting optimal targets in ClinRO and PRO. This post hoc analysis investigates the impact of achieving individual optimal targets or MDA on patient health-related quality of life (HRQoL) outcomes in patients with atopic dermatitis.</p><p><strong>Methods: </strong>Patients from phase 3 Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD UP (NCT03568318) were randomized 1:1:1 to receive daily oral upadacitinib at either 15 mg or 30 mg, or placebo for the first 16 weeks. Patients were pooled for this analysis regardless of intervention and stratified into three mutually exclusive response groups meeting optimal, moderate, or neither treatment target for each ClinRO or PRO, and the achievement of MDA at week 16. Impact on the patient's HRQoL was measured across eight outcomes: itch, skin symptoms, quality of life, sleep, daily activities, emotional state, work productivity, and treatment satisfaction.</p><p><strong>Results: </strong>Patients who achieved optimal treatment targets, compared with those achieving moderate or neither treatment target, reported greater improvement in patient HRQoL outcomes (1.1-20.2-fold for optimal versus moderate, 1.3 to > 50-fold for optimal versus neither target, and 1.2-16.3-fold for moderate versus neither target groups). In addition, patients who achieved MDA, versus those achieving optimal ClinRO or PRO alone, were more likely to report improved patient HRQoL outcomes.</p><p><strong>Conclusions: </strong>These results highlight the value of reaching optimal treatment targets and MDA in disease management of atopic dermatitis.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2255-2273"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144495001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}